Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
CRBU Caribou Biosciences	$0.94 +11.7%	$0.86	$0.66 ▼ $3.45	$87.28M	2.36	1.51 million shs	1.19 million shs
INZY Inozyme Pharma	$3.95 +178.2%	$1.09	$0.72 ▼ $6.24	$255.02M	1.35	743,804 shs	49.78 million shs
JMAC Maxpro Capital Acquisition	$4.89 +5.7%	$6.66	$7.50 ▼ $19.22	$65.66M	0.01	74,040 shs	9,697 shs
LSTA Lisata Therapeutics	$2.63 +9.6%	$2.25	$1.87 ▼ $4.20	$22.66M	0.95	21,709 shs	57,124 shs

Metaverse Stocks And Why You Can't Ignore Them

Thinking about investing in Meta, Roblox, or Unity? Enter your email to learn what streetwise investors need to know about the metaverse and public markets before making an investment.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
CRBU Caribou Biosciences	+11.73%	+21.19%	+28.00%	-30.49%	-74.22%
INZY Inozyme Pharma	+178.17%	+240.52%	+310.69%	+188.32%	-15.42%
JMAC Maxpro Capital Acquisition	0.00%	-13.56%	-17.41%	-30.94%	+1,283.10%
LSTA Lisata Therapeutics	+9.58%	+25.24%	+26.44%	+4.78%	-7.54%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
CRBU Caribou Biosciences	2.8336 of 5 stars	3.5	3.0	0.0	0.0	1.8	3.3	0.6
INZY Inozyme Pharma	2.9579 of 5 stars	4.3	3.0	0.0	0.0	2.1	2.5	0.0
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	2.8577 of 5 stars	3.5	5.0	0.0	0.0	0.0	0.0	1.3

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
CRBU Caribou Biosciences	3.00	Buy	$7.40	688.58% Upside
INZY Inozyme Pharma	2.50	Moderate Buy	$11.75	197.47% Upside
JMAC Maxpro Capital Acquisition	0.00	N/A	N/A	N/A
LSTA Lisata Therapeutics	3.00	Buy	$15.00	470.34% Upside

Current Analyst Ratings Breakdown

Latest LSTA, JMAC, INZY, and CRBU Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/16/2025	INZY Inozyme Pharma	Wedbush Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Strong-Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Downgrade	Moderate Buy ➝ Hold
5/16/2025	INZY Inozyme Pharma	Wells Fargo & Company Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Overweight ➝ Equal Weight	$4.00
5/16/2025	INZY Inozyme Pharma	Jefferies Financial Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Hold	$15.00 ➝ $4.00
5/14/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Buy ➝ Buy	$15.00 ➝ $12.00
4/28/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $3.00
4/10/2025	INZY Inozyme Pharma	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$16.00 ➝ $16.00
4/8/2025	INZY Inozyme Pharma	Needham & Company LLC Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$15.00 ➝ $15.00
3/19/2025	CRBU Caribou Biosciences	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$9.00 ➝ $9.00
3/12/2025	INZY Inozyme Pharma	Raymond James Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Outperform ➝ Outperform	$24.00 ➝ $12.00
3/11/2025	INZY Inozyme Pharma	Piper Sandler Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Overweight ➝ Overweight	$30.00 ➝ $23.00

(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
CRBU Caribou Biosciences	$9.92M	8.80	N/A	N/A	$4.17 per share	0.23
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	$2.27 per share	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	$1M	22.66	N/A	N/A	$5.88 per share	0.45

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
CRBU Caribou Biosciences	-$102.07M	-$1.62	N/A	N/A	N/A	-1,290.81%	-45.46%	-38.07%	8/5/2025 (Estimated)
INZY Inozyme Pharma	-$71.17M	-$1.63	N/A	N/A	N/A	N/A	-88.42%	-57.02%	8/5/2025 (Estimated)
JMAC Maxpro Capital Acquisition	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	-$20.84M	-$2.30	N/A	N/A	N/A	N/A	-51.19%	-45.16%	N/A

Latest LSTA, JMAC, INZY, and CRBU Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
5/14/2025	Q1 2025	INZY Inozyme Pharma	-$0.43	-$0.44	-$0.01	-$0.44	N/A	N/A
5/8/2025	Q1 2025	CRBU Caribou Biosciences	-$0.43	-$0.43	N/A	-$0.43	$1.48 million	$2.35 million
5/8/2025	Q1 2025	LSTA Lisata Therapeutics	-$0.53	-$0.55	-$0.02	-$0.55	N/A	N/A
3/10/2025	Q4 2024	CRBU Caribou Biosciences	-$0.40	-$0.39	+$0.01	-$0.39	$2.11 million	$2.08 million
2/27/2025	Q4 2024	LSTA Lisata Therapeutics	-$0.76	-$0.55	+$0.21	-$0.55	N/A	$1.00 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
INZY Inozyme Pharma	N/A	N/A	N/A	N/A	N/A
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
CRBU Caribou Biosciences	N/A	7.38	7.38
INZY Inozyme Pharma	0.51	7.68	7.68
JMAC Maxpro Capital Acquisition	N/A	N/A	N/A
LSTA Lisata Therapeutics	N/A	8.03	8.03

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
CRBU Caribou Biosciences	77.51%
INZY Inozyme Pharma	88.30%
JMAC Maxpro Capital Acquisition	73.18%
LSTA Lisata Therapeutics	8.94%

Insider Ownership

Company	Insider Ownership
CRBU Caribou Biosciences	8.28%
INZY Inozyme Pharma	12.18%
JMAC Maxpro Capital Acquisition	19.27%
LSTA Lisata Therapeutics	9.60%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
CRBU Caribou Biosciences	100	93.01 million	81.95 million	Optionable
INZY Inozyme Pharma	50	64.56 million	57.05 million	Optionable
JMAC Maxpro Capital Acquisition	2,021	13.43 million	10.84 million	Not Optionable
LSTA Lisata Therapeutics	30	8.62 million	7.63 million	Not Optionable

LSTA, JMAC, INZY, and CRBU Headlines

Recent News About These Companies

Lisata Therapeutics, Inc. (NASDAQ:LSTA) Q1 2025 Earnings Call Transcript

May 10, 2025 | msn.com

Lisata Therapeutics Inc (LSTA) Q1 2025 Earnings Call Highlights: Strategic Advances Amid Market ...

May 10, 2025 | finance.yahoo.com

Lisata Therapeutics’ Earnings Call Highlights Progress

May 9, 2025 | tipranks.com

Lisata Therapeutics Reports Q1 2025 Financial Results

May 9, 2025 | tipranks.com

Lisata Therapeutics, Inc. (LSTA) Q1 2025 Earnings Conference Call Transcript

May 8, 2025 | seekingalpha.com

Lisata eyes key trial milestones in 2025 as certepetide development gains momentum

May 8, 2025 | proactiveinvestors.com

Lisata Therapeutics Reports First Quarter 2025 Financial Results and Provides Business Update

May 8, 2025 | globenewswire.com

Lisata Therapeutics to Report First Quarter 2025 Financial Results and Provide a Business Update on Thursday, May 8, 2025

May 1, 2025 | globenewswire.com

Lisata Therapeutics talks ADC breakthrough with Catalent – ICYMI

April 19, 2025 | proactiveinvestors.com

Lisata, Catalent partner for cancer drug research

April 17, 2025 | uk.investing.com

Lisata Therapeutics signs research license with Catalent

April 15, 2025 | proactiveinvestors.com

Lisata Therapeutics Announces Research License with Catalent

April 15, 2025 | globenewswire.com

Lisata Therapeutics CEO discusses AI drug discovery collaboration - ICYMI

March 8, 2025 | proactiveinvestors.com

Lisata Therapeutics And GATC Health Partner To Accelerate Drug Development Using AI Technology

March 7, 2025 | nasdaq.com

Lisata Therapeutics to Present at the Investival Showcase USA

March 6, 2025 | globenewswire.com

Lisata Therapeutics, GATC Health consummate first step in collaboration

March 5, 2025 | markets.businessinsider.com

Lisata Therapeutics partners with GATC Health to advance AI-driven drug development

March 5, 2025 | proactiveinvestors.com

Lisata Therapeutics and GATC Health Consummate First Step in Strategic Collaboration to use AI to Derisk and Accelerate Drug Development

March 5, 2025 | globenewswire.com

Lisata Therapeutics’ Earnings Call: Progress Amid Challenges

February 28, 2025 | tipranks.com

Lisata Therapeutics Inc (LSTA) Q4 2024 Earnings Call Highlights: Promising Developments Amid ...

February 28, 2025 | finance.yahoo.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LSTA, JMAC, INZY, and CRBU Company Descriptions

Caribou Biosciences NASDAQ:CRBU

$0.94 +0.10 (+11.73%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$0.94 0.00 (-0.36%)

As of 05/16/2025 07:52 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Inozyme Pharma NASDAQ:INZY

$3.95 +2.53 (+178.17%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$3.94 -0.01 (-0.13%)

As of 05/16/2025 07:58 PM Eastern

Inozyme Pharma, Inc., a clinical-stage rare disease biopharmaceutical company, focuses on developing novel therapeutics for the treatment of vasculature, soft tissue, and skeleton diseases. The company's lead product candidate is INZ-701, a soluble, recombinant, genetically engineered, and fusion protein for the treatment of ENPP1 and ABCC6 deficiencies, as well as patients with end-stage kidney disease receiving hemodialysis. It has a license agreement with Yale University for specified therapeutic and prophylactic products. The company was incorporated in 2015 and is headquartered in Boston, Massachusetts.

Maxpro Capital Acquisition NASDAQ:JMAC

$4.89 +0.27 (+5.73%)

As of 05/16/2025

Maxpro Capital Acquisition Corp. does not have significant operations. It intends to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization, or similar business combination with one or more businesses. The company was incorporated in 2021 and is based in Taipei City, Taiwan.

Lisata Therapeutics NASDAQ:LSTA

$2.63 +0.23 (+9.58%)

Closing price 05/16/2025 04:00 PM Eastern

Extended Trading

$2.77 +0.14 (+5.32%)

As of 05/16/2025 05:25 PM Eastern

Lisata Therapeutics, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of innovative therapies for the treatment of solid tumors and other diseases. Its product candidates include LSTA1, which is in Phase 2a and 2b clinical studies for the treatment of solid tumor, including metastatic pancreatic ductal adenocarcinoma (mPDAC), in combination with a range of anti-cancer regimens; XOWNA that is in Phase IIa clinical trial for the treatment of coronary microvascular dysfunction; and CD34+ cell therapy for the treatment of chronic kidney disease. Lisata Therapeutics, Inc. was incorporated in 1980 and is headquartered in Basking Ridge, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time